Tagged with Lilly,

Germany The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes Pharma’s plans to spend EUR 25 million euros to enhance its production capabilities.   Eli Lilly plans new 2 billion…

Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines.   Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…

UK The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell therapy agreement and GSK’s acquisition of Bellus Health.   More evidence needed on Lilly’s weight loss drug, UK watchdog says…

Global Eli Lilly recently revealed more than promising clinical trial results for its Alzheimer’s candidate, donanemab, showing that the drug slows Alzheimer’s by as much as 60 percent in mild cases. While safety concerns about the drug remain, Lilly is hoping for an FDA approval by the end of the year.…

Belgium Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical trials. Pharma industry leaders and Belgian government officials weigh in on the factors threatening the country’s position as a clinical…

United Kingdom Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British government has announced a GBP 650 million “Life Sci for Growth” package along with some pro-innovation regulation and a review…

USA Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken its indignation a step further and sued the US government, arguing that the new legislation violates the constitution, but shareholders at the ICCR are not…

Belgium Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains behind many of its European counterparts. In a recent roadmap, the minister of health set out to improve the country’s…

Belgium Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its European Clinical Trial Services (ELECTS) division, and his aim to reach 200,000 patients in Belgium with Lilly treatments before the…

USA After considerable government pressure to reduce insulin costs in the US, Eli Lilly recently slashed its prices by as much as 70 percent, followed by competitors Novo Nordisk and Sanofi. While these steps to make insulin more affordable, together with the US Medicare insulin price cap that came into effect…

UK A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding downturn and Gilead’s Yescarta approval from NICE.   Northern Ireland Medicines supply still ‘problematic and inefficient’ (BBC News) According to…

Africa Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant Eli Lilly and Egyptian group EVA Pharma. The agreement will allow Lilly products to be manufactured in, and for, the…